MYNZ Relative Valuation
MYNZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MYNZ is overvalued; if below, it's undervalued.
Historical Valuation
Mainz Biomed NV (MYNZ) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.55. The fair price of Mainz Biomed NV (MYNZ) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.17
Fair
-0.56
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Mainz Biomed NV. (MYNZ) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.41
EV/EBIT
Mainz Biomed NV. (MYNZ) has a current EV/EBIT of -0.41. The 5-year average EV/EBIT is -2.16. The thresholds are as follows: Strongly Undervalued below -6.83, Undervalued between -6.83 and -4.50, Fairly Valued between 0.17 and -4.50, Overvalued between 0.17 and 2.50, and Strongly Overvalued above 2.50. The current Forward EV/EBIT of -0.41 falls within the Historic Trend Line -Fairly Valued range.
6.70
PS
Mainz Biomed NV. (MYNZ) has a current PS of 6.70. The 5-year average PS is 55.39. The thresholds are as follows: Strongly Undervalued below -104.52, Undervalued between -104.52 and -24.56, Fairly Valued between 135.35 and -24.56, Overvalued between 135.35 and 215.31, and Strongly Overvalued above 215.31. The current Forward PS of 6.70 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Mainz Biomed NV. (MYNZ) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.94. The thresholds are as follows: Strongly Undervalued below -12.29, Undervalued between -12.29 and -7.62, Fairly Valued between 1.73 and -7.62, Overvalued between 1.73 and 6.40, and Strongly Overvalued above 6.40. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.28
P/FCF
Mainz Biomed NV. (MYNZ) has a current P/FCF of -0.28. The 5-year average P/FCF is -0.13. The thresholds are as follows: Strongly Undervalued below -0.51, Undervalued between -0.51 and -0.32, Fairly Valued between 0.06 and -0.32, Overvalued between 0.06 and 0.25, and Strongly Overvalued above 0.25. The current Forward P/FCF of -0.28 falls within the Historic Trend Line -Fairly Valued range.
Mainz Biomed NV (MYNZ) has a current Price-to-Book (P/B) ratio of 1.90. Compared to its 3-year average P/B ratio of 4.29 , the current P/B ratio is approximately -55.71% higher. Relative to its 5-year average P/B ratio of 5.90, the current P/B ratio is about -67.85% higher. Mainz Biomed NV (MYNZ) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -162.69%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -120.48% , the current FCF yield is about -100.00% lower.
1.90
P/B
Median3y
4.29
Median5y
5.90
-246.01
FCF Yield
Median3y
-162.69
Median5y
-120.48
Competitors Valuation Multiple
The average P/S ratio for MYNZ's competitors is 0.00, providing a benchmark for relative valuation. Mainz Biomed NV Corp (MYNZ) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MYNZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MYNZ in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Mainz Biomed NV (MYNZ) currently overvalued or undervalued?
What is Mainz Biomed NV (MYNZ) fair value?
How does MYNZ's valuation metrics compare to the industry average?
What is the current P/B ratio for Mainz Biomed NV (MYNZ) as of Dec 05 2025?
What is the current FCF Yield for Mainz Biomed NV (MYNZ) as of Dec 05 2025?
What is the current Forward P/E ratio for Mainz Biomed NV (MYNZ) as of Dec 05 2025?